🇺🇸 FDA
Patent

US 7572887

Gene expressed in prostate cancer, methods and use thereof

granted A61KA61K38/164A61K38/168

Quick answer

US patent 7572887 (Gene expressed in prostate cancer, methods and use thereof) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K38/164, A61K38/168, A61K47/64